Literature DB >> 28057717

Pathology-Driven Comprehensive Proteomic Profiling of the Prostate Cancer Tumor Microenvironment.

Lisa Staunton1, Claire Tonry1, Rosina Lis2, Virginia Espina3, Lance Liotta3, Rosanna Inzitari1, Michaela Bowden2, Aurelie Fabre1,4, John O'Leary5, Stephen P Finn5, Massimo Loda2,6, Stephen R Pennington7.   

Abstract

Prostate cancer is the second most common cancer in men worldwide. Gleason grading is an important predictor of prostate cancer outcomes and is influential in determining patient treatment options. Clinical decisions based on a Gleason score of 7 are difficult as the prognosis for individuals diagnosed with Gleason 4+3 cancer is much worse than for those diagnosed with Gleason 3+4 cancer. Laser capture microdissection (LCM) is a highly precise method to isolate specific cell populations or discrete microregions from tissues. This report undertook a detailed molecular characterization of the tumor microenvironment in prostate cancer to define the proteome in the epithelial and stromal regions from tumor foci of Gleason grades 3 and 4. Tissue regions of interest were isolated from several Gleason 3+3 and Gleason 4+4 tumors using telepathology to leverage specialized pathology expertise to support LCM. Over 2,000 proteins were identified following liquid chromatography tandem mass spectrometry (LC-MS/MS) analysis of all regions of interest. Statistical analysis revealed significant differences in protein expression (>100 proteins) between Gleason 3 and Gleason 4 regions-in both stromal and epithelial compartments. A subset of these proteins has had prior strong association with prostate cancer, thereby providing evidence for the authenticity of the approach. Finally, validation of these proteins by immunohistochemistry has been obtained using an independent cohort of prostate cancer tumor specimens.Implications: This unbiased strategy provides a strong foundation for the development of biomarker protein panels with significant diagnostic and prognostic potential. Mol Cancer Res; 15(3); 281-93. ©2017 AACR. ©2017 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28057717     DOI: 10.1158/1541-7786.MCR-16-0358

Source DB:  PubMed          Journal:  Mol Cancer Res        ISSN: 1541-7786            Impact factor:   5.852


  7 in total

Review 1.  Cancer proteogenomics: current impact and future prospects.

Authors:  D R Mani; Karsten Krug; Bing Zhang; Shankha Satpathy; Karl R Clauser; Li Ding; Matthew Ellis; Michael A Gillette; Steven A Carr
Journal:  Nat Rev Cancer       Date:  2022-03-02       Impact factor: 60.716

Review 2.  Quantitative Mass Spectrometry-Based Proteomic Profiling for Precision Medicine in Prostate Cancer.

Authors:  Amilcar Flores-Morales; Diego Iglesias-Gato
Journal:  Front Oncol       Date:  2017-11-07       Impact factor: 6.244

3.  Integrative proteomics in prostate cancer uncovers robustness against genomic and transcriptomic aberrations during disease progression.

Authors:  Leena Latonen; Ebrahim Afyounian; Antti Jylhä; Janika Nättinen; Ulla Aapola; Matti Annala; Kati K Kivinummi; Teuvo T L Tammela; Roger W Beuerman; Hannu Uusitalo; Matti Nykter; Tapio Visakorpi
Journal:  Nat Commun       Date:  2018-03-21       Impact factor: 14.919

4.  Quantitative proteomic analysis of prostate tissue specimens identifies deregulated protein complexes in primary prostate cancer.

Authors:  Bo Zhou; Yiwu Yan; Yang Wang; Sungyong You; Michael R Freeman; Wei Yang
Journal:  Clin Proteomics       Date:  2019-04-13       Impact factor: 3.988

5.  Direct molecular dissection of tumor parenchyma from tumor stroma in tumor xenograft using mass spectrometry-based glycoproteomics.

Authors:  Xiaoying Ye; Brian T Luke; Bih-Rong Wei; Jan A Kaczmarczyk; Jadranka Loncarek; Jennifer E Dwyer; Donald J Johann; Richard G Saul; Dwight V Nissley; Frank McCormick; Gordon R Whiteley; Josip Blonder
Journal:  Oncotarget       Date:  2018-05-29

Review 6.  On the Road to Accurate Protein Biomarkers in Prostate Cancer Diagnosis and Prognosis: Current Status and Future Advances.

Authors:  Yiwu Yan; Su Yeon Yeon; Chen Qian; Sungyong You; Wei Yang
Journal:  Int J Mol Sci       Date:  2021-12-17       Impact factor: 5.923

Review 7.  Ion Channel Profiling in Prostate Cancer: Toward Cell Population-Specific Screening.

Authors:  Valerio Farfariello; Natalia Prevarskaya; Dimitra Gkika
Journal:  Rev Physiol Biochem Pharmacol       Date:  2021       Impact factor: 5.545

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.